Tafinlar + Mekinist [1]
Tafinlar + Mekinist [1]
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.1,2
Please select treatment of BRAF-positive metastatic melanoma below to find out more; then, consider treatment from a patient perspective by clicking on ‘Management of patients with BRAF positive melanoma’.
References
- Tafinlar (dabrafenib) Summary of Product Characteristics.
- Mekinist (trametinib) Summary of Product Characteristics.